Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma
|ClinicalTrials.gov Identifier: NCT00641095|
Recruitment Status : Unknown
Verified November 2008 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : March 21, 2008
Last Update Posted : August 12, 2013
Information provided by:
National Cancer Institute (NCI)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||September 2010|
|Study Completion Date :||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26.